Mga Batayang Estadistika
| LEI | 529900A43X33ON524197 |
| CIK | 1262104 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MEI Pharma, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
MEI PHARMA, INC. 32,309,944 Shares of Common Stock Offered by the selling stockholders TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-289312 PROSPECTUS MEI PHARMA, INC. 32,309,944 Shares of Common Stock Offered by the selling stockholders This prospectus filed by MEI Pharma, Inc. (the “Company”) relates to the resale, from time to time by the selling stockholders named in this prospectus, or the selling stockholders, of up to (i) 25,301,407 shares (the “PI |
|
| September 4, 2025 |
Exhibit 10.1 MASTER LOAN AGREEMENT This Master Loan Agreement (the “Agreement”) is dated as of 3rd of September, 2025 by and between BitGo Prime, LLC (“BitGo,” “BitGo Prime,” or “Lender”), a limited liability company organized and existing under the laws of Delaware, and MEI Pharma, Inc. (“Borrower”), a corporation organized and existing under the laws of Delaware (each, a “Party” and together, th |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 3, 2025 MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41827 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| August 26, 2025 |
As filed with the Securities and Exchange Commission on August 26, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 26, 2025 Registration Statement No. |
|
| August 6, 2025 |
Exhibit 107 Calculation of Filing Fee Tables MEI Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equi |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2025 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 6, 2025 Registration Statement No. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2025 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 5, 2025 |
MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising SAN DIEGO, 5 August 2025 – MEI Pharma, Inc. |
|
| July 30, 2025 |
FORM 8-K Item 3.02 Unregistered Sales of Equity Securities. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 23, 2025 |
Up to $100,000,000 of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-277201 PROSPECTUS SUPPLEMENT (To Prospectus dated February 28, 2024) Up to $100,000,000 of Common Stock We have entered into an At the Market Offering Agreement, or Sales Agreement, with Titan Partners Group LLC, a division of American Capital Partners, LLC, or Titan, dated July 22, 2025, relating to shares of our common sto |
|
| July 22, 2025 |
Exhibit 99.1 MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange • Charlie Lee, the Founder of Litecoin and a lead investor in the PIPE, will join the Board of Directors of the Company effective upon the closing of the Private Placement • GSR, a preeminent digital asset market maker an |
|
| July 22, 2025 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT MEI PHARMA, INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 22, 2025 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 17, 2025, is entered into by and among MEI Pharma, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “I |
|
| July 22, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 17, 2025, between MEI Pharma, Inc., a corporation organized under the laws of State of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subje |
|
| July 22, 2025 |
MEI PHARMA, INC. Common Stock ($0.00000002 par value per share) AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 MEI PHARMA, INC. Common Stock ($0.00000002 par value per share) AT THE MARKET OFFERING AGREEMENT July 22, 2025 Titan Partners Group LLC, a division of American Capital Partners, LLC 4 World Trade Center, 29th Floor New York, NY 10007 Ladies and Gentlemen: MEI Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and |
|
| July 22, 2025 |
Exhibit 10.7 STRATEGIC ADVISOR AGREEMENT THIS STRATEGIC ADVISOR AGREEMENT (this “Agreement”) is made and entered into as of July 22, 2025 (the “Effective Date”) by and between MEI Pharma, Inc., a Delaware corporation (the “Company”), and Green Grass Ventures (the “Strategic Advisor”, and with the Company, the “Parties”). WHEREAS, the Company wishes to secure the commitment of Strategic Advisor to |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41827 51-0407811 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 22, 2025 |
Exhibit 10.6 Advisory Agreement This agreement (the "Agreement") is made effective as of July 22, 2025 by MEI Pharma, Inc., a Delaware corporation (the "Company"), and Green Dragon Investments LLC (the "Advisor”). WHEREAS, the Board of Directors of the Company (“Board”) desires to obtain the advice and counsel of the Advisor regarding but not limited to the Services described on Schedule 1; and WH |
|
| July 22, 2025 |
COMMON STOCK PURCHASE WARRANT MEI PHARMA, INC. Exhibit 4.4 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIE |
|
| July 22, 2025 |
COMMON STOCK PURCHASE WARRANT MEI PHARMA, INC. Exhibit 4.6 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIE |
|
| July 22, 2025 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT July 17, 2025 Titan Partners Group LLC, a division of American Capital Partners, LLC 4 World Trade Center, 29th Floor New York, NY 10007 Ladies and Gentlemen: Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which Titan Partners Group LLC, a division of American Capital Partners, LLC (“Titan Partners” or the “Placemen |
|
| July 22, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT MEI PHARMA, INC. Exhibit 4.3 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIE |
|
| July 22, 2025 |
Exhibit 10.5 July 22, 2025 GSR Strategies LLC c/o Corporation Service Company 251 Little Falls Drive, Wilmington, DE 19808 Email: [email protected]; [email protected] Attn: Legal & Compliance Re: Side Letter - Board Nominee Right Ladies and Gentlemen, This letter agreement will confirm our agreement that, in connection with and effective as of the purchase of 1,461,988 shares of Common Stock, $0.00000 |
|
| July 22, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT MEI PHARMA, INC. Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIE |
|
| July 22, 2025 |
COMMON STOCK PURCHASE WARRANT MEI PHARMA, INC. Exhibit 4.5 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIE |
|
| July 22, 2025 |
Exhibit 10.4 ASSET MANAGEMENT AGREEMENT This ASSET MANAGEMENT AGREEMENT (this “Agreement”), effective July 22, 2025 (the “Effective Date”), is entered into by and between MEI Pharma, Inc. (the “Client”), and GSR Strategies LLC (the “Asset Manager”). WHEREAS, the Client wishes to appoint the Asset Manager to manage certain assets of the Client; and WHEREAS, the Asset Manager wishes to be appointed |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41827 MEI Pharma, Inc. |
|
| May 13, 2025 |
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position Evaluation of Strategic Alternatives is Ongoing SAN DIEGO-(BUSINESS WIRE) — May 13, 2025 – MEI Pharma, Inc. |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2025 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 7, 2025 |
Execution Copy Exhibit 10.1 11455 El Camino Real, Suite 250 San Diego, CA 92130 (858) 369-7100 March 3, 2025 Dear Justin, This Amended and Restated Employment Agreement (this “Agreement”), effective as of March 3, 2025 (the “Effective Date”), confirms the terms of your employment with MEI Pharma, Inc. (“MEI”). WHEREAS, you are currently employed by MEI pursuant to the terms of the letter agreement |
|
| February 12, 2025 |
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position Evaluation of Strategic Alternatives is Ongoing SAN DIEGO-(BUSINESS WIRE) — February 12, 2025 – MEI Pharma, Inc. |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41827 MEI Pharma, Inc. |
|
| January 31, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41827 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| November 14, 2024 |
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position Reaffirms Continuation of Evaluation of Strategic Alternatives SAN DIEGO-(BUSINESS WIRE) — November 12, 2024 – MEI Pharma, Inc. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| November 12, 2024 |
Exhibit 10.5 CONSULTING SERVICES AGREEMENT Amended September 13, 2024 THIS CONSULTING SERVICES AGREEMENT (this “Agreement”) is entered into as of August 2, 2024 by and between MEI Pharma, Inc. (the “Company”), and David Urso (“Consultant”). AGREEMENT WHEREAS, the Company wishes to obtain the services of Consultant, and Consultant wishes to provide such services, subject to the terms and condition |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41827 MEI Pharma, Inc. |
|
| November 12, 2024 |
Exhibit 10.4 CONSULTING SERVICES AGREEMENT Amended September 13, 2024 THIS CONSULTING SERVICES AGREEMENT (this “Agreement”) is entered into as of August 2, 2024 by and between MEI Pharma, Inc. (the “Company”), and Dr. Richard Ghalie (“Consultant”). AGREEMENT WHEREAS, the Company wishes to obtain the services of Consultant, and Consultant wishes to provide such services, subject to the terms and co |
|
| November 12, 2024 |
Exhibit 10.3 Separation and Release Agreement This Separation and Release Agreement (“Agreement”) is made between you, David Urso, and MEI Pharma, Inc., and sets forth the terms of your separation from employment with MEI Pharma, Inc. and its affiliates (“MEI”). This Agreement will become effective upon the “Effective Date” as specified in Section 10(i), below. Once effective, this Agreement will |
|
| November 12, 2024 |
Exhibit 10.2 Separation and Release Agreement This Separation and Release Agreement (“Agreement”) is made between you, Dr. Richard Ghalie, and MEI Pharma, Inc., and sets forth the terms of your separation from employment with MEI Pharma, Inc. and its affiliates (“MEI”). This Agreement will become effective upon the “Effective Date” as specified in Section 10(i), below. Once effective, this Agreeme |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41827 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| October 25, 2024 |
Execution Version Exhibit 2.1 ASSET PURCHASE AGREEMENT between AARDVARK THERAPEUTICS, INC., as Purchaser and MEI PHARMA, INC., as Seller Dated as of October 22, 2024 Table of Contents Page No. Article I DEFINITIONS 1.1 Definitions 1 1.2 Interpretation 8 Article II PURCHASE & SALE OF PURCHASED ASSETS 9 2.1 Purchased Assets 9 2.2 Excluded Assets 10 2.3 Assumed Liabilities 11 2.4 Excluded Liabilities |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 19, 2024 |
Addendum to Employment Agreement between MEI Pharma, Inc. and Justin J. File, dated August 1, 2024 Exhibit 10.24 Execution Copy Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Mr. Justin "Jay" File c/o 11455 El Camino Real, Suite 250 San Diego, CA 92130 Dear Jay, This addendum (this “Addendum”) to your Employment Agreement with MEI Pharma. Inc., dated June 9, 2023 (t |
|
| September 19, 2024 |
MEI Pharma Reports Fiscal Year End 2024 Cash Position Confirms Continuation of Evaluation of Strategic Alternatives SAN DIEGO-(BUSINESS WIRE) — September 19, 2024 – MEI Pharma, Inc. |
|
| September 19, 2024 |
Exhibit 97 Compensation Recoupment Policy of MEI Pharma, Inc. Effective as of October 2, 2023 Article A. Purpose and General Terms Section A-1. Purpose. MEI Pharma, Inc. (the “Company”) has adopted this Compensation Recoupment Policy (this “Policy”) to: (a) implement a mandatory clawback policy in the event of a Restatement in compliance with the applicable rules of the Nasdaq exchange, which is s |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 30, 2024 |
Voruciclib: An Oral CDK9 Inhibitor for AML and Other Malignancies July 2024 Voruciclib: An Oral CDK9 Inhibitor for AML and Other Malignancies July 2024 Forward Looking Statements Certain information contained in this communication that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding: the potential, saf |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2024 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 22, 2024 |
Exhibit 99.1 MEI Pharma to Consider Strategic Alternatives Company Commences a Cash Preservation Plan Including a Reduction in Force SAN DIEGO-(BUSINESS WIRE)—July 22, 2024 – MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including potential transactions as well as a |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2024 MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41827 51-0407811 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 21, 2024 |
NASDAQ: MEIP Corporate Overview Novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies May 21, 2024 Forward Looking Statements Certain information contained in this communication that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 incl |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41827 MEI Pharma, Inc. |
|
| May 9, 2024 |
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights - Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients - - Board of Directors Unanimously Aligned on Prioritization of Voruciclib Program Development- - MEI Begins Fourth Fiscal Quarter with $56. |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 9, 2024 |
Amended and Restated 2008 Stock Omnibus Equity Compensation Plan (December 2023) MEI PHARMA, INC. AMENDED AND RESTATED 2008 STOCK OMNIBUS EQUITY COMPENSATION PLAN Effective as of December 18, 2023 Section 1. Purpose The Plan authorizes the Compensation Committee to provide Advisors, Employees and Non-Employee Directors that are providing services to the Company or its Affiliates, who are in a position to contribute to the long-term success of the Company or its Affiliates, wit |
|
| February 28, 2024 |
Up to $9,906,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-277201 PROSPECTUS SUPPLEMENT (To Prospectus dated February 28, 2024) Up to $9,906,000 of Common Stock We have entered into a Capital on DemandTM Sales Agreement, or Sales Agreement, with JonesTrading Institutional Services LLC, or JonesTrading, dated February 20, 2024, relating to shares of our common stock, par value $0.00000002 per share, or |
|
| February 26, 2024 |
February 26, 2024 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 21, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 21, 2024 |
Exhibit 1.1 MEI PHARMA, INC. Common Stock ($0.00000002 par value per share) Capital on Demand™ Sales Agreement February 20, 2024 JonesTrading Institutional Services LLC 325 Hudson Street 6th Floor New York, New York 10013 Ladies and Gentlemen: MEI Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time t |
|
| February 20, 2024 |
As filed with the Securities and Exchange Commission on February 20, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 20, 2024 Registration Statement No. |
|
| February 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) MEI Pharma, Inc. |
|
| February 14, 2024 |
US55279B3015 / MEI Pharma, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41827 MEI Pharma, Inc. |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 13, 2024 |
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights SAN DIEGO – February 13, 2024 – MEI Pharma, Inc. |
|
| February 13, 2024 |
Amended and Restated Certificate of Incorporation of MEI Pharma, Inc. Exhibit 3.2 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MEI PHARMA, INC. MEI PHARMA, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware, which was originally incorporated under the name, Marshall Edwards, Inc. (the “Corporation”), does hereby certify as follows: FIRST. Upon the filing and effectiveness (the “Ef |
|
| February 13, 2024 |
US55279B3015 / MEI Pharma, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01438-meipharmainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: MEI Pharma Inc Title of Class of Securities: Common Stock CUSIP Number: 55279B301 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the ru |
|
| February 13, 2024 |
Employment Agreement between MEI Pharma, Inc. and Richard Ghalie dated January 16, 2024 Exhibit 10.4 11455 El Camino Real, Suite 250 San Diego, CA 92130 (858) 369-7100 January 16, 2024 Dr. Richard Ghalie 4755 Natalie Drive, San Diego, CA. 92115 Dear Richard, On behalf of MEI Pharma, Inc. (“MEI”), this letter agreement (this “Agreement”) confirms the terms of your continued employment with MEI as the Chief Medical Officer of MEI (“CMO”), reporting to the Chief Executive Officer (the “ |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 26, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 26, 2023 |
BDO USA, P.C. letter dated December 26, 2023 Exhibit 16.1 December 26, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on December 19, 2023, to be filed by our former client, MEI Pharma, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, /s/ |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 22, 2023 |
Sixth Amended and Restated Bylaws of MEI Pharma, Inc. adopted as of December 18, 2023 Exhibit 3.1 SIXTH AMENDED AND RESTATED BYLAWS OF MEI PHARMA, INC. ADOPTED AS OF DECEMBER 18, 2023 ARTICLE I OFFICES SECTION 1. Registered Office. The registered office of the Corporation, and the registered agent of the Corporation at the address of such registered office, shall be as set forth in the Certificate of Incorporation of the Corporation, as amended and/or restated from time to time (th |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 11, 2023 |
Exhibit 99.1 MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023 – Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity – – Initial Results from Correlative Studies Demonstrate On-target Reductions in Mcl-1 and RNA Pol II p-S2 – SAN DIEGO – December 11, 2023 – MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage p |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41827 MEI Pharma, Inc. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 MEI Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 9, 2023 |
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights SAN DIEGO – November 9, 2023 – MEI Pharma, Inc. |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 1, 2023 |
Cooperation Agreement, dated as of October 31, 2023, by and among the Investors and the Company Exhibit 10.1 Execution Copy COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), effective as of October 31, 2023 (the “Effective Date”), is entered into by and among: • MEI Pharma, Inc., a Delaware corporation (the “Company”); • Funicular Funds, LP, a Delaware limited partnership (“Funicular”), Cable Car Capital LLC, a California limited liability company (“Cable Car”) and Jacob M |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| November 1, 2023 |
SC 13D/A 1 sc13da81339200411012023.htm AMENDMENT NO. 8 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 8)1 MEI Pharma, Inc. (Name of Issuer) Common Stock, $0.00000002 par value (Title |
|
| November 1, 2023 |
Exhibit 99.1 MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital Commits to Capital Return of Up to $3.15 per Share Adds Three New Directors and Forms Capital Allocation Committee of the Board SAN DIEGO, TORONTO and SAN FRANCISCO – November 1, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) and Anson Funds and Cable Car Capital (“Anson and Cable Car”) today announced tha |
|
| November 1, 2023 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41827 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 27, 2023 |
Table of Contents - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 24, 2023 |
SC 13D/A 1 sc13da71339200410242023.htm AMENDMENT NO. 7 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 7)1 MEI Pharma, Inc. (Name of Issuer) Common Stock, $0.00000002 par value (Title |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 17, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Consent Revocation Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Consent Revocation Statement ☐ Confidential, for Use of the Commission On |
|
| October 13, 2023 |
SC 13D/A 1 sc13da61339200410132023.htm AMENDMENT NO. 6 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)1 MEI Pharma, Inc. (Name of Issuer) Common Stock, $0.00000002 par value (Title |
|
| October 12, 2023 |
Justin W. Chairman +1.215.963.5061 [email protected] October 12, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Perry Hindin, Esquire Re: MEI Pharma, Inc. Preliminary Consent Revocation Statement on Schedule 14A filed September 15, 2023 File No. 000-50484 To Whom it May Concern: On behalf of MEI Pharma, In |
|
| October 12, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Consent Revocation Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Consent Revocation Statement ☐ Confidential, for Use of the Commission On |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Consent Statement ☐ Confidential, for |
|
| October 3, 2023 |
EX-4.1 Exhibit 4.1 MEI Pharma, Inc. and Computershare, Inc., as Rights Agent Rights Agreement Dated as of October 1, 2023 TABLE OF CONTENTS Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 5 Section 3. Issue of Right Certificates 6 Section 4. Form of Right Certificates 7 Section 5. Countersignature and Registration 8 Section 6. Transfer, Split Up, Combination and Exchan |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 1, 2023 MEI PHARMA, INC. (Exact Name of Registrant Specified in Charter) Delaware 000-50484 51-0407811 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 3, 2023 |
Exhibit 99.1 MEI Pharma Adopts Limited-Duration Stockholder Rights Plan - Responds to Substantial Stock Accumulation by Anson Advisors and Cable Car Capital - - Protects Long-Term Value of All Stockholders’ Investments in MEI Pharma - San Diego – October 2, 2023 – MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced |
|
| October 3, 2023 |
Certification of Designation of Series A Junior Participating Preferred Stock EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATION of SERIES A JUNIOR PARTICIPATING PREFERRED STOCK of MEI PHARMA, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) MEI Pharma, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (hereinafter called the “Corporation”), hereby certifies that the following resolution was adopted by the |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 MEI PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 51-0407811 State of incorporation or organization) (I.R.S. Employer Identification No.) 11455 El Camino Real, Suite |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Consent Statement ☐ Confidential, for |
|
| September 28, 2023 |
Justin W. Chairman +1.215.963.5061 [email protected] September 28, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: MEI Pharma, Inc. Preliminary Consent Revocation Statement on Schedule 14A filed September 15, 2023 File No. 000-50484 To Whom it May Concern: On behalf of MEI Pharma, Inc. (the “Company”), we subm |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Consent Revocation Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Consent Revocation Statement ☐ Confidential, for Use of the Commission On |
|
| September 26, 2023 |
Exhibit 99.1 MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights — Conference Call Today at 5:00 p.m. Eastern Time — SAN DIEGO – September 26, 2023 – MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023. “Over just the next few quarters we look forwar |
|
| September 26, 2023 |
SC 13D/A 1 sc13da51339200409262023.htm AMENDMENT NO. 5 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 MEI Pharma, Inc. (Name of Issuer) Common Stock, $0.00000002 par value (Title |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Consent Statement ☐ Confidential, for |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 26, 2023 |
Description of MEI Common Stock Exhibit 4.4 DESCRIPTION OF MEI COMMON STOCK The following descriptions of MEI Common Stock, provisions of the MEI COI, and the MEI Bylaws are summaries and are qualified by reference to such MEI COI and MEI Bylaws and applicable provisions of Delaware corporate law. MEI has filed copies of these documents with the SEC as exhibits to its periodic filings. Authorized Common Stock Under the MEI COI, |
|
| September 26, 2023 |
Exhibit 10.22 FORM OF WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 September 26, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 MEI Pharma, Inc. (Name of Issuer) Common Stock, $0.00000002 par value (Title of Class of Securities) 55279B202 (CUSIP Number) JACOB MA-WEAVER CABLE CAR |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No. ) 1. Name of the Registrant: MEI Pharma, Inc. [CIK: 0001262104] 2. Name of Person Relying on Exemption: Scott Klarquist 3. Address of Person Relying on the Exemption: Available Upon Request 4. Written Material. The following written materials are |
|
| September 18, 2023 |
September 18, 2023 VIA EDGAR U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 RE: MEI Pharma, Inc. Commission File Number: 000-50484 Preliminary Consent Revocation Materials Ladies and Gentlemen: On behalf of MEI Pharma, Inc., a Delaware corporation (the “Company”), we are transmitting for filing under Rule 14a-6(a) of the Securities Exchange Act of 1934, as amend |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 15, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Consent Revocation Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Consent Revocation Statement ☐ Confidential, for Use of the Commission Onl |
|
| September 15, 2023 |
SC 13D/A 1 sc13da31339200409152023.htm AMENDMENT NO. 3 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 MEI Pharma, Inc. (Name of Issuer) Common Stock, $0.00000002 par value (Title |
|
| September 15, 2023 |
JOINT FILING AND SOLICITATION AGREEMENT EX-99.1 2 ex991to13da313392004091523.htm JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.1 JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of MEI Pharma, Inc., a Delaware corporation (the “Company”); and WHEREAS, Cable Car Capital LLC, Funicular Funds, LP, and Jacob Ma-Weaver (together, “Cable Car”) and Anson Investments Master |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 MEI Pharma, Inc. (Name of Issuer) Common Stock, $0.00000002 par value (Title of Class of Securities) 55279B202 (CUSIP Number) JACOB MA-WEAVER CABLE CAR |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Consent Statement ☐ |
|
| July 27, 2023 |
Exhibit 10.1 Separation and Release Agreement This Separation and Release Agreement (“Agreement”) is made between you, Brian G. Drazba, and MEI Pharma, Inc., and sets forth the terms of your separation from employment with MEI Pharma, Inc. and its affiliates (“MEI”). This Agreement will become effective upon the “Effective Date” as specified in Section 11(a), below. Once effective, this Agreement |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 26, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 24, 2023 |
EX-10.1 Exhibit 10.1 July 23, 2023 VIA EMAIL AND HAND DELIVERY Infinity Pharmaceuticals, Inc. 1100 Massachusetts Avenue, Floor 4 Cambridge, Massachusetts 02138 Attention: General Counsel Email: [email protected] RE: Termination Notice Dear Seth: Reference is hereby made to that certain Agreement and Plan of Merger, dated as of February 22, 2023, by and among Infinity Pharmaceuticals, Inc. (“Iri |
|
| July 24, 2023 |
MEI Pharma Announces Results of Special Meeting of Stockholders EX-99.1 Exhibit 99.1 MEI Pharma Announces Results of Special Meeting of Stockholders SAN DIEGO, July 23, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that, based on a count of the votes cast at the Company’s Special Meeting of Stockholders, MEI, by a narrow margin, did not obtain the necessary stockholder votes to approve the merger agreement with Infinity Pharmaceuticals |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 23, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 19, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 14, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Consent Statement ☐ C |
|
| July 19, 2023 |
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction EX-99.1 Exhibit 99.1 MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction SAN DIEGO, July 19, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company’s special meeting on July 23, 2023. MEI issued the following statement |
|
| July 19, 2023 |
EX-10.1 Exhibit 10.1 Certain identified information has been excluded from this Exhibit 10.1 because it is both not material and would likely cause competitive harm to MEI Pharma, Inc. if publicly disclosed. The redacted portions are marked as [*CONFIDENTIAL*]. Execution Version Termination Agreement This Termination Agreement (this “Termination Agreement”) is made and entered into effective as of |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 14, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 18, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 18, 2023 |
11455EI Camino Real, Suite 250, San Diego, CA 92130 EX-99.1 Exhibit 99.1 July 17, 2023 Cable Car Capital LLC 601 California Street, Suite 1151 San Francisco, CA 94108 Attention: Jacob Ma-Weaver, Managing Member Anson Advisors, Inc. 155 University Avenue, Suite 207 Toronto, ON, Canada, M5H 3B7 Attention: Moez Kassam, Director Dear Messrs. Ma-Weaver and Kassam: I am in receipt of your letter dated July 17, 2023 (“Record Date Request Letter”). The Rec |
|
| July 18, 2023 |
MEI Pharma Responds to Anson and Cable Car EX-99.2 Exhibit 99.2 MEI Pharma Responds to Anson and Cable Car SAN DIEGO, July 18, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following statement in response to the Consent Solicitation launched by Anson Advisors Inc. and Cable Car Capital LLC on July 17, 2023: Anson and Cable Car have launched a process, called a consent solicitation, in an attempt to take control of |
|
| July 18, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 18, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Consent Statement ☐ C |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 17, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 17, 2023 |
Exhibit 99.1 Anson and Cable Car FILE PRELIMINARY CONSENT MATERIALS TO REMOVE ENTIRE BOARD OF DIRECTORS AT MEI Pharma, Inc. Believe the Board Needs to be Held Accountable for its Poor Judgment and Value-Destructive Initiatives Reiterate their Concern that the Board is Not Acting in the Best Interest of Stockholders Believe Immediate Action Must be Taken to Prevent the Further Destruction of Value |
|
| July 17, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 17, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Consent Statement ☐ C |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 MEI Pharma, Inc. (Name of Issuer) Common Stock, $0.00000002 par value (Title of Class of Securities) 55279B202 (CUSIP Number) JACOB MA-WEAVER CABLE CAR |
|
| July 17, 2023 |
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction EX-99.1 Exhibit 99.1 MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction SAN DIEGO, July 17, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company’s special meeting on July 23, 202 |
|
| July 13, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-271481 MEI Pharma, Inc. (“MEI”) has filed a registration statement on Form S-4, as amended (File No. 333-271481) (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. The Registration Statement relates to an offering of securities of MEI to stockholders |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 13, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 13, 2023 |
MEI Pharma Postpones Special Meeting of Shareholders EX-99.1 Exhibit 99.1 MEI Pharma Postpones Special Meeting of Shareholders SAN DIEGO, July 13, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that it has postponed its special meeting in connection with the proposed transaction with Infinity Pharmaceuticals, Inc. (“Infinity”) to July 23, 2023, at 10:00 a.m. Eastern Time, unless postponed or adjourned to a later date. MEI iss |
|
| July 13, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 13, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No. ) 1. Name of the Registrant: MEI Pharma, Inc. [CIK: 0001262104] 2. Name of Person Relying on Exemption: Scott Klarquist 3. Address of Person Relying on the Exemption: Available Upon Request 4. Written Material. The following written materials are |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 7, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 7, 2023 |
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals EX-99.1 Exhibit 99.1 MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals Glass Lewis Joins ISS in Recommending that MEI Shareholders Vote FOR the Infinity Transaction SAN DIEGO, July 7, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ( |
|
| July 7, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 7, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 5, 2023 |
EX-99.2 Exhibit 99.2 Alliance Advisors 200 Broadacres Drive, 3rd Fl. Bloomfield, NJ 07003 PRESORT FIRST CLASS U.S. POSTAGE PAID So. HACKENSACK, NJ PERMIT #251 Attention MEI Pharma Shareholders An Important Special Meeting is Approaching Your Vote Matters – Vote Today A special meeting of shareholders is scheduled for July 14, 2023. MEI Board of Directors recommends you vote FOR the pending Infinit |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 5, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 5, 2023 |
EX-99.1 Exhibit 99.1 MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals Affirms Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals Highlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Progr |
|
| July 5, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 July 5, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 3, 2023 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-271481 MEI Pharma, Inc. (“MEI”) has filed a registration statement on Form S-4, as amended (File No. 333-271481) (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. The Registration Statement relates to an offering of securities of MEI to stockh |
|
| June 29, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 29, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| June 29, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 29, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 29, 2023 |
EX-99.1 Exhibit 99.1 MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals Highlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Programs Combined Company Well-Positioned to Make a Difference in Cancer Care With Significant Potential to D |
|
| June 28, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 27, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 27, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 28, 2023 |
MEI Pharma Responds to Anson and Cable Car EX-99.1 Exhibit 99.1 MEI Pharma Responds to Anson and Cable Car SAN DIEGO, June 27, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following statement in response to the disclosure made today by Anson Advisors Inc. and Cable Car Capital LLC: Anson and Cable Car reiterated their formerly disclosed, unsolicited and non-binding proposal that our Board of Directors previously |
|
| June 28, 2023 |
MEI Pharma Responds to Anson and Cable Car EX-99.1 Exhibit 99.1 MEI Pharma Responds to Anson and Cable Car SAN DIEGO, June 27, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following statement in response to the disclosure made today by Anson Advisors Inc. and Cable Car Capital LLC: Anson and Cable Car reiterated their formerly disclosed, unsolicited and non-binding proposal that our Board of Directors previously |
|
| June 20, 2023 |
425 1 d485555d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 15, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporat |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 15, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 20, 2023 |
EX-99.1 Exhibit 99.1 MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates Event Available at 8:00 a.m. Eastern Time on June 19, 2023 SAN DIEGO, CA. and CAMBRIDGE, MA., June 15, 2023 – MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new |
|
| June 20, 2023 |
EX-99.2 JUNE 2023 MEI Pharma & Infinity Pharmaceuticals Merger and Clinical Program Update Exhibit 99.2 A Transaction with Potential to Create Significant Opportunities and Build Value TODAY’S AGENDA Welcome and Overview David Urso, President & CEO (MEIP and combined company) Eganelisib Dr. Robert Ilaria, Jr., Chief Medical Officer (INFI and combined company) Dr. Ezra Cohen Chief Medical Officer, |
|
| June 14, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MEI PHARMA, INC. |
|
| June 14, 2023 |
S-8 Registration No. 333- As filed with the Securities and Exchange Commission on June 13, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 51-0407811 (State or other jurisdiction of incorporation or organization) (IRS Employe |
|
| June 13, 2023 |
EX-10.1 Exhibit 10.1 Execution Copy MEI PHARMA, INC. EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT In consideration of my employment or continued employment by MEI Pharma, Inc. (the “Company”), and the compensation now and hereafter paid to me, I hereby agree as follows: 1. NONDISCLOSURE 1.1 Recognition of Company’s Rights; Nondisclosure. At all times during my employment and thereafte |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 9, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 13, 2023 |
EX-10.2 Exhibit 10.2 Execution Copy 11455 El Camino Real, Suite 250 San Diego, CA 92130 (858) 369-7100 June 9, 2023 Dear Jay, On behalf of MEI Pharma, Inc. (“MEI”), this letter agreement (the “Agreement”) confirms the terms of your employment with MEI, commencing June 12, 2023. As of June 12, 2023, you will be appointed and serve as Executive Vice President of Finance of MEI (“EVP Finance”). The B |
|
| June 13, 2023 |
EX-99.1 Exhibit 99.1 MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor SAN DIEGO, June 13, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company’s succession planning, Brian Drazba’s tenur |
|
| June 13, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 9, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 13, 2023 |
Amended and Restated MEI Pharma, Inc. 2021 Inducement Grant Equity Compensation Plan EX-10.3 Exhibit 10.3 MEI PHARMA, INC. AMENDED & RESTATED 2021 INDUCEMENT GRANT EQUITY COMPENSATION PLAN Section 1. Purpose The Plan is intended to assist the Company and its Affiliates, in attracting and retaining selected individuals to serve as employees who are expected to contribute to the Company’s success, by providing an inducement material for such individuals to enter into employment with |
|
| June 6, 2023 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-271481 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the stockholders of MEI Pharma, Inc. and Infinity Pharmaceuticals, Inc.: The boards of directors of MEI Pharma, Inc., a Delaware corporation (“MEI”) and Infinity Pharmaceuticals Inc., a Delaware corporation (“Infinity”), have agreed upon a transaction in which Infinit |
|
| June 5, 2023 |
EX-10.39 Exhibit 10.39 INFINITY PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Inducement Grant Pursuant to NASDAQ Stock Market Rule 5635(c)(4) 1.Grant of Option. This agreement (the “Agreement”) evidences the grant by Infinity Pharmaceuticals, Inc. (the “Company”) on [], 201[] (the “Grant Date”) to [], an employee of the Company (the “Participant”), of an option (the “Option”) to purch |
|
| June 5, 2023 |
EX-99.7 Exhibit 99.7 CONSENT OF AQUILO PARTNERS We hereby consent to the inclusion of our opinion letter, dated February 22, 2023 (the “Opinion Letter”), addressed to the Board of Directors of Infinity Pharmaceuticals, Inc. (the “Company”), included as Annex C to the joint proxy statement/prospectus contained in that certain registration statement on Form S-4/A (the “Registration Statement”) of ME |
|
| June 5, 2023 |
EX-10.28 Exhibit 10.28 OFFICE LEASE 1100 MASSACHUSETTS AVENUE, CAMBRIDGE, MA Landlord : Sun Life Assurance Company of Canada Tenant : Infinity Pharmaceuticals, Inc. Date : April 3, 2019 This Lease consists of four parts: Part I Cover Sheet Part II Standard Lease Provisions Part III Additional Provisions (if any) and Part IV Exhibits EXHIBIT A—Floor Plan of Premises EXHIBIT B—Tenant Improvements EX |
|
| June 5, 2023 |
EX-10.22 Exhibit 10.22 EXECUTION VERSION TERMINATION AND REVISED RELATIONSHIP AGREEMENT This Termination and Revised Relationship Agreement (this “Agreement”) is entered into as of the 17 th day of July 2012 (the “Effective Date”) by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having its principal office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and |
|
| June 5, 2023 |
EX-10.20 Exhibit 10.20 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECE |
|
| June 5, 2023 |
Form of Infinity Nonstatutory Stock Option Agreement under 2010 Stock Incentive Plan. EX-10.37 Exhibit 10.37 INFINITY PHARMACEUTICALS, INC. Nonstatutory Stock Option Granted Under 2010 Stock Incentive Plan (the “Plan”) 1. Grant of Option. It is intended that the option shall not be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). Except as otherwise indicated by the context |
|
| June 5, 2023 |
Form of Stock Option Agreement under Infinity 2019 Equity Incentive Plan. EX-10.43 Exhibit 10.43 INFINITY PHARMACEUTICALS, INC. STOCK OPTION AGREEMENT Infinity Pharmaceuticals, Inc. (the “ Company ”) hereby grants the following stock option pursuant to its 2019 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “ Participant ”): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Num |
|
| June 5, 2023 |
EX-10.50 Exhibit 10.50 Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com February 22, 2023 Stéphane Peluso 1100 Massachusetts Avenue Cambridge, MA 02138 Dear Stéphane: As you know, Infinity Pharmaceuticals, Inc. (“Infinity”) is entering into a merger agreement with MEI Pharma, Inc. (“MEI”) by which, if the merger is completed in accordance with its terms, Infinity will become a subsid |
|
| June 5, 2023 |
Amendment No. 3 to Infinity 2010 Stock Incentive Plan. EX-10.32 Exhibit 10.32 INFINITY PHARMACEUTICALS, INC. 2010 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2010 Stock Incentive Plan (the “Plan”) of Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contrib |
|
| June 5, 2023 |
Amendment No. 6 to Infinity 2010 Stock Incentive Plan. EX-10.35 Exhibit 10.35 AMENDMENT NO. 6 TO 2010 STOCK INCENTIVE PLAN OF INFINITY PHARMACEUTICALS, INC. The 2010 Stock Incentive Plan, as amended (the “Plan”) of Infinity Pharmaceuticals, Inc. is hereby amended as follows: 1. Sections 6(a), (b), and (c) of the Plan are hereby deleted and new Sections 6(a), (b), and (c) are inserted in lieu thereof which shall read as follows: “(a) Initial Grant . Up |
|
| June 5, 2023 |
EX-10.48 Exhibit 10.48 AMENDMENT NO. 1 TO INFINITY PHARMACEUTICALS, INC. EXECUTIVE SEVERANCE BENEFITS PLAN The Executive Severance Benefits Plan (the “Plan”) of Infinity Pharmaceuticals, Inc. is hereby amended as follows: 1. Section 3(h) of the Plan is hereby deleted and a new Section 3(h) is inserted in lieu thereof which shall read as follows: “(h) “ Covered Employees ” shall mean all Regular Fu |
|
| June 5, 2023 |
EX-10.53 Exhibit 10.53 THIS IS AN IMPORTANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. February 23, 2023 VIA HAND DELIVERY Lawrence Bloch P.O. Box 650129 West Newton, MA 02465 Re: Severance Agreement and Release Dear Lawrence: This letter summarizes the terms of your separation from employment with Infinity Pharmaceuticals Inc (the “Company”) |
|
| June 5, 2023 |
EX-10.49 Exhibit 10.49 Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com February 22, 2023 Robert Ilaria 1100 Massachusetts Avenue Cambridge, MA 02138 Dear Robert: As you know, Infinity Pharmaceuticals, Inc. (“Infinity”) is entering into a merger agreement with MEI Pharma, Inc. (“MEI”) by which, if the merger is completed in accordance with its terms, Infinity will become a subsidiary |
|
| June 5, 2023 |
EX-10.46 Exhibit 10.46 1100 Massachusetts Ave Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com August 11, 2021 Robert L. Ilaria, Jr., M.D. 9 Highview Terrace Madison, NJ 07940 Dear Robert, On behalf of Infinity Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Senior Vice President, Chief Medical Officer reporting to Adelene Perkins, Chief Executive Off |
|
| June 5, 2023 |
EX-10.41 Exhibit 10.41 INFINITY PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT AGREEMENT Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) Infinity Pharmaceuticals, Inc. (the “Company”) hereby grants the following restricted stock units. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of restrict |
|
| June 5, 2023 |
Form of Infinity Incentive Stock Option Agreement under 2010 Stock Incentive Plan. EX-10.36 Exhibit 10.36 INFINITY PHARMACEUTICALS, INC. STOCK OPTION AGREEMENT Infinity Pharmaceuticals, Inc. (the “ Company ”) hereby grants the following stock option pursuant to its 2019 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “ Participant ”): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Num |
|
| June 5, 2023 |
EX-10.27 EXHIBIT 10.27 Execution Version NOVATION AND AMENDMENT AGREEMENT This Novation and Amendment Agreement (this “Agreement”) is made as of January 27, 2020, by and among Infinity Pharmaceuticals, Inc. (the “Company”), BVF Partners L.P. (“BVF”), Royalty Security Holdings, LLC (“Holdco”), and Royalty Security, LLC (“Buyer”). Each of the Company, BVF, Holdco and Buyer are referred to herein ind |
|
| June 5, 2023 |
EX-10.26 EXHIBIT 10.26 Execution Version FUNDING AGREEMENT This Funding Agreement (this “Agreement”), dated as of January 8, 2020, is entered into by and among Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), BVF Partners L.P., a Delaware limited partnership (“BVF”) and Royalty Security, LLC, a wholly owned subsidiary of BVF and a Delaware limited liability company (“Buyer”) |
|
| June 5, 2023 |
EX-10.25 Exhibit 10.25 Execution Version PROTECTIVE RIGHTS AGREEMENT THIS PROTECTIVE RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 11, 2019 by and between Infinity Pharmaceuticals, Inc., a Delaware corporation (“Grantor”), and HCR Collateral Management, LLC, a Delaware limited liability company (“Agent”), as agent for HealthCare Royalty Partners III, L.P., a Delaware lim |
|
| June 5, 2023 |
EX-10.23 Exhibit 10.23 EXECUTION VERSION TERMINATION AND REVISED RELATIONSHIP AGREEMENT This Termination and Revised Relationship Agreement (this “Agreement”) is entered into as of the 17th day of July 2012 (the “Effective Date”) by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having its principal office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and |
|
| June 5, 2023 |
EX-10.16 Exhibit 10.16 AMENDMENT TO AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT This Amendment to Amended and Restated Development and License Agreement (“Amendment”) is made as of this 29th day of July, 2014 (the “Amendment Effective Date”) by and between Intellikine LLC, a limited liability company organized and existing under the laws of the State of Delaware and successor to Intelli |
|
| June 5, 2023 |
Form of MEI Pharma, Inc. Proxy Card. EX-99.1 Exhibit 99.1 MMMMMMMMMMMMMM C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext ENDORSEMENTLINE SACKPACK 000000000.000000 ext 000000000.000000 ext MR A SAMPLE DESIGNATION (IF ANY) ADD 1 000001 ADD 2 Your vote matters – here’s how to vote! ADD 3 You may vote online or by phone instead of mailing this card. ADD 4 MMMMMMMMM ADD 5 Online ADD 6 Go to w |
|
| June 5, 2023 |
EX-10.52 Exhibit 10.52 Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com February 22, 2023 Seth Tasker 1100 Massachusetts Avenue Cambridge, MA 02138 Dear Seth: As you know, Infinity Pharmaceuticals, Inc. (“Infinity”) is entering into a merger agreement with MEI Pharma, Inc. (“MEI”) by which, if the merger is completed in accordance with its terms, Infinity will become a subsidiary of |
|
| June 5, 2023 |
Infinity Pharmaceuticals, Inc. Executive Severance Benefits Plan effective February 6, 2013. EX-10.47 Exhibit 10.47 Infinity Pharmaceuticals, Inc. Executive Severance Benefits Plan 1. Establishment of Plan. Infinity Pharmaceuticals, Inc. (the “Company”) hereby establishes an unfunded severance benefits plan (the “Plan”) that is intended to be a welfare benefit plan within the meaning of Section 3(1) of ERISA. The Plan is in effect for Covered Employees who experience a Covered Termination |
|
| June 5, 2023 |
EX-10.40 Exhibit 10.40 INFINITY PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) 1. Grant of Option. This agreement (the “Agreement”) evidences the grant by Infinity Pharmaceuticals, Inc. (the “Company”) on [] (the “Grant Date”) to [], an employee of the Company (the “Participant”), of an option (the “Option”) to purchase, o |
|
| June 5, 2023 |
Amendment No. 2 to Infinity 2010 Stock Incentive Plan. EX-10.31 Exhibit 10.31 AMENDMENT NO. 2 TO INFINITY PHARMACEUTICALS, INC. 2010 STOCK INCENTIVE PLAN The 2010 Stock Incentive Plan, as amended (the “Plan”) of Infinity Pharmaceuticals, Inc. is hereby amended as follows: Section 4(a)(1) of the Plan is hereby deleted and a new Section 4(a)(1) is inserted in lieu thereof which shall read as follows: “(1) Authorized Number of Shares. Subject to adjustme |
|
| June 5, 2023 |
EX-10.24 Exhibit 10.24 Execution Version PURCHASE AND SALE AGREEMENT dated as of March 5, 2019 between INFINITY PHARMACEUTICALS, INC. and HEALTHCARE ROYALTY PARTNERS III, L.P. Table of Contents Page ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 6 ARTICLE II PURCHASE AND SALE OF THE PURCHASED ASSETS Section 2.1 Purchase and Sale 8 Se |
|
| June 5, 2023 |
EX-10.19 Exhibit 10.19 AMENDMENT No. 4 TO AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT This Amendment No. 4 to Amended and Restated Development and License Agreement (“Amendment No. 4”) is made as of this 4 th day of March, 2019 (the “Amendment No. 4 Effective Date”) by and between Intellikine LLC, a limited liability company organized and existing under the laws of the State of Delaware |
|
| June 5, 2023 |
EX-10.18 Exhibit 10.18 AMENDMENT No. 3 TO AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT This Amendment No. 3 to Amended and Restated Development and License Agreement (“Amendment No. 3”) is made as of this 26 th day of July, 2017 (the “Amendment No. 3 Effective Date”) by and between Intellikine LLC, a limited liability company organized and existing under the laws of the State of Delaware |
|
| June 5, 2023 |
MEI Pharma, Inc. 11455 El Camino Real, Suite 250 San Diego, California 92130 CORRESP MEI Pharma, Inc. 11455 El Camino Real, Suite 250 San Diego, California 92130 June 5, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Re: MEI Pharma, Inc. Registration Statement on Form S-4 File No. 333-271481 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 |
|
| June 5, 2023 |
EX-10.17 Exhibit 10.17 AMENDMENT No. 2 TO AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT This Amendment No. 2 to Amended and Restated Development and License Agreement (the “Amendment No. 2”) is made as of this 27 th day of September, 2016 (the “Amendment 2 Effective Date”) by and between Intellikine LLC, a limited liability company organized and existing under the laws of the State of Del |
|
| June 5, 2023 |
Amendment No. 1 to Infinity 2010 Stock Incentive Plan. EX-10.30 Exhibit 10.30 AMENDMENT NO. 1 TO INFINITY PHARMACEUTICALS, INC. 2010 STOCK INCENTIVE PLAN The Infinity Pharmaceuticals, Inc. 2010 Stock Incentive Plan be and hereby is amended by deleting Sections 6(a), 6(b) and 6(c) in their entirety and replacing them with the following: * * * 6. Director Options (a) Initial Grant. Upon the commencement of service on the Board by any individual who is n |
|
| June 5, 2023 |
Amendment No. 4 to Infinity 2010 Stock Incentive Plan. EX-10.33 Exhibit 10.33 INFINITY PHARMACEUTICALS, INC. 2010 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2010 Stock Incentive Plan (the “Plan”) of Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contrib |
|
| June 5, 2023 |
EX-10.15 Exhibit 10.15 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. EXECUTION VERSION December 24, 2012 AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT Between INTELLIKINE LLC and INFINITY PHARMACEUTICALS, INC. |
|
| June 5, 2023 |
Amendment No. 5 to Infinity 2010 Stock Incentive Plan. EX-10.34 Exhibit 10.34 INFINITY PHARMACEUTICALS, INC. 2010 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2010 Stock Incentive Plan (the “ Plan ”) of Infinity Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important con |
|
| June 5, 2023 |
Offer Letter between Infinity Pharmaceuticals, Inc. and Stephane Peluso, Ph.D., dated July 12, 2021. EX-10.45 Exhibit 10.45 1100 Massachusetts Ave Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com July 12, 2021 Stephane Peluso, Ph.D. 38 Algonquian Drive Natick, MA 01760 Dear Stephane, On behalf of Infinity Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Senior Vice President, Chief Scientific Officer reporting to Adelene Perkins, Chief Executive Offic |
|
| June 5, 2023 |
EX-10.21 Exhibit 10.21 CONFIDENTIAL Execution Version Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDED AND RESTATED LICENSE AGREEMENT BY AND BETWEEN INFINITY PHARMACEUTICALS, INC. AND VERASTEM, INC. CONFIDENTIAL LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”) is entered into |
|
| June 5, 2023 |
Infinity 2019 Equity Incentive Plan. EX-10.42 Exhibit 10.42 INFINITY PHARMACEUTICALS, Inc. 2019 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2019 Equity and Incentive Plan (the “Plan”) of Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important c |
|
| June 5, 2023 |
Form of Infinity Restricted Stock Agreement under 2010 Stock Incentive Plan. EX-10.38 Exhibit 10.38 Form RSA INFINITY PHARMACEUTICALS, INC. RESTRICTED STOCK AGREEMENT Infinity Pharmaceuticals, Inc. (the “ Company ”) has selected you to receive the following restricted stock award pursuant to its 2010 Stock Incentive Plan, as amended. The terms and conditions attached hereto are also a part hereof . Notice of Grant Name of recipient (the “ Participant ”): [Name] Grant Date: |
|
| June 5, 2023 |
2010 Infinity Stock Incentive Plan. EX-10.29 Exhibit 10.29 INFINITY PHARMACEUTICALS, INC. 2010 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2010 Stock Incentive Plan (the “ Plan ”) of Infinity Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important con |
|
| June 5, 2023 |
EX-10.44 Exhibit 10.44 INFINITY PHARMACEUTICALS, Inc. 2019 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2019 Equity and Incentive Plan (the “Plan”) of Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important c |
|
| June 5, 2023 |
EX-10.51 Exhibit 10.51 Cambridge, MA Tel: 617-453-1000 Fax: 617-453-1001 www.infi.com February 22, 2023 Adelene Perkins 1100 Massachusetts Avenue Cambridge, MA 02138 Dear Adelene: As you know, Infinity Pharmaceuticals, Inc. (“Infinity”) is entering into a merger agreement with MEI Pharma, Inc. (“MEI”) by which, if the merger is completed in accordance with its terms, Infinity will become a subsidi |
|
| June 5, 2023 |
Form of Infinity Pharmaceuticals, Inc. Proxy Card. EX-99.2 Exhibit 99.2 SCAN TO VIEW MATERIALS & VOTE w INFINITY PHARMACEUTICALS INC. VOTE BY INTERNET C/O AMERICAN STOCK TRANSFER & TRUST CO., LTD. Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above 6201 15TH AVE. BROOKLYN, NY 11219 Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 P.M. Eastern Time on July 13, 2023 |
|
| June 5, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on June 2, 2023 Registration No. |
|
| June 2, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 31, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| June 2, 2023 |
CEO Employment Agreement between the Company and David Urso, dated June 2, 2023. EX-10.1 2 d484383dex101.htm EX-10.1 Exhibit 10.1 Execution Copy 11455 El Camino Real, Suite 250 San Diego, CA 92130 (858) 369-7100 June 2, 2023 Dear David, On behalf of MEI Pharma, Inc. (“MEI”), this letter agreement (the “Agreement”) confirms the terms of your continued employment with MEI and your appointment as the President and Chief Executive Officer of MEI (“CEO”), reporting to the Board of |
|
| June 2, 2023 |
EX-99.1 Exhibit 99.1 MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor SAN DIEGO, June 2, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company’s previously announced succession plan, Daniel P. |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 31, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| June 2, 2023 |
EX-10.1 Exhibit 10.1 Execution Copy 11455 El Camino Real, Suite 250 San Diego, CA 92130 (858) 369-7100 June 2, 2023 Dear David, On behalf of MEI Pharma, Inc. (“MEI”), this letter agreement (the “Agreement”) confirms the terms of your continued employment with MEI and your appointment as the President and Chief Executive Officer of MEI (“CEO”), reporting to the Board of Directors of MEI (the “Board |
|
| June 2, 2023 |
EX-99.1 Exhibit 99.1 MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor SAN DIEGO, June 2, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company’s previously announced succession plan, Daniel P. |
|
| June 1, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 1, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 June 1, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 1, 2023 |
MEI Pharma Board of Directors Rejects Unsolicited Proposal EX-99.1 2 d438169dex991.htm EX-99.1 Exhibit 99.1 MEI Pharma Board of Directors Rejects Unsolicited Proposal SAN DIEGO, June 1, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that its Board of Directors (the “Board”) reviewed and rejected the unsolicited and non-binding proposal received on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LL |
|
| May 31, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 30, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 31, 2023 |
MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal EX-99.1 Exhibit 99.1 MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal SAN DIEGO, May 30, 2023 – MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today confirmed receipt of an unsolicited and non-binding proposal on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC, as referenced in their 13-D filing of earlier today, to acquire all outstanding sha |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 30, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 30, 2023 |
begin 644 ex991to13d13392meip05302023.pdf M)5!$1BTQ+C8-)>+CS],-"C8S(# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#,@,5T^/G-TTZ!Q(!VD F^9^!<=TW@ # !B;#B\-"F5N M9'-T%LP(# @-C$R(#=6=N0PX"! MRMKL>&=V#LVG<90 #DJ"D $H!X3O@G)!2MP\< ,'E ^A&X(*0(A0@E(@W #W M$&V]$$(.$@\@%" =?#DX8*,\S8MH'<\UO92*W'.XZ/?9T:TYCDQL2'$<"0I8 M*<9Y9O!L.I44%L]0="EF)?H4KA(51:HNG1?Y/-+FBIT?CME4WYI9OW%(KV. MB]@D><:&:3SS0[UGV2N1Y,?IQ!8WS.,]/4[@W* |
|
| May 30, 2023 |
Exhibit 99.2 May 23, 2023 Charles V. Baltic III, Chairman MEI Pharma, Inc. 11455 El Camino Real, Suite 250 San Diego, California 92130 CONFIDENTIAL Dear Mr. Baltic: We represent holders (the “Group” or “we”) of 988,930 shares of MEI Pharma, Inc. (“MEIP” or the “Company”), comprising approximately 14.8% of the outstanding common stock of the Company. With this letter (this “Acquisition Proposal”), |
|
| May 30, 2023 |
MEIP / MEI Pharma Inc / Anson Funds Management LP - THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 MEI Pharma Inc. (Name of Issuer) Common Stock, $0.00000002 par value (Title of Class of Securities) 55279B202 (CUSIP Number) JACOB MA-WEAVER CABLE CAR C |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50484 MEI Pharma, Inc. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934 May 11, 2023 Date of report (Date of earliest event reported) MEI Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50484 51-0407811 (State or other jurisdiction of incorporation) (Commission File Numbe |
